Lapaquistat-d9 Acetate

• Catalog No.: L175502
• M. F.: C33H41ClN2O9
• M. W.: 645.13964

SYNONYMS

• IUPAC name: 2-(1-{2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl}(^2H₉)piperidin-4-yl)acetic acid
• IUPAC Traditional name: (1-{2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-3,5-dihydro-4,1-benzoxazepin-3-yl]acetyl}(^2H₉)piperidin-4-yl)acetic acid
• Synonyms: (3R-trans)-1-[[1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid-d9; TAK 475-d9; 1-[2-[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid-d9

DETAILS

Description (English)

A novel labelled squalene synthase inhibitor. Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100. Treatment with Lapaquistat acetate increased collagen concentration and transformed coron

REFERENCES

• Amano, Y., et al.: Eur. J. Pharmacol., 466, 155 ( 2003), Hiyoshi, H., et al.: J. Lipid Res., 44, 128 (2003)
• Miki, T., et al.: J. Med. Chem., 45, 4571 (2003)
• Shiomi, M., et al.: Atherosclerosis, 178, 287 (2003)